Chronic HCV infection is a global health problem that affects> 184 million people worldwide.
HCV is associated with several hepatic and extrahepatic disorders, including several …

Background Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer and
a leading cause of cancer-related deaths worldwide. The major risk factors for HCC …

Background & Aims We performed a prospective study to investigate the effects of a
sustained viral response (SVR) on outcomes of patients with hepatitis C virus (HCV) …

Abstract Data from the 2003‐2010 National Health and Nutrition Examination Survey
(NHANES) indicate that about 3.6 million people in the United States have antibodies to the …

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. A
single‐nucleotide polymorphism (SNP), rs6834314, was associated with serum liver …

With no approved pharmacological treatment, nonalcoholic fatty liver disease (NAFLD) is
now the most common cause of chronic liver disease in Western countries and its worldwide …

Background: Sofosbuvir and ledipasvir, which have recently been approved for treatment of
chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old …

Background: The prevalence of hepatitis C virus (HCV) in US prisoners is high; however,
HCV testing and treatment are rare. Infected inmates released back into society contribute to …

Oral direct‐acting antivirals (DAAs) represent a major advance in hepatitis C virus (HCV)
treatment. Along with recent updates in HCV screening policy and expansions in insurance …

Globally, up to approximately 800,000 new cases of hepatocellular carcinoma (HCC) are
diagnosed annually. 1, 2 The incidence of cirrhosis-related HCC is rising in the United …